EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Decoupling Behavioral Domains via Kynurenic Acid Analog Optimization: Implications for Schizophrenia and Parkinson’s Disease Therapeutics

Diána Martos iD, Bálint Lőrinczi iD, István Szatmári iD, László Vécsei, Masaru Tanaka iD

Cells · 2025

DOI: 10.3390/cells14130973 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Diána Martos und 4 weiteren Autor:innen. Beteiligte Einrichtung: HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged Danube Neuroscience Research Laboratory, Tisza Lajos krt. …. Hauptthemen laut MEDLINE: Kynurenic Acid, Schizophrenia, Parkinson Disease, Behavior, Animal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Research, Development, and Innovation Office-NKFIH K138125, SZTE SZA-OK-KKA, HUN-REN Hungarian Research Network, National Research, Development, and Innovation Office.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kynurenic acid (KYNA), a putative neuroprotective agent, modulates glutamatergic pathways in schizophrenia and Parkinson’s disease but is limited by acute motor activity impairments (e.g., ataxia). Research leveraging animal disease models explores its structure–activity relationship to enhance therapeutic efficacy while mitigating adverse effects, addressing global neuropsychiatric disorders affecting over 1 billion people. Structural analogs of KYNA (SZR-72, SZR-73, and SZR-81) were designed to uncouple therapeutic benefits from motor toxicity; yet, systematic comparisons of their acute behavioral profiles remain unexplored. Here, we assess the motor safety, time-dependent effects, and therapeutic potential of these analogs in mice. Using acute intracerebroventricular dosing, we evaluated motor coordination (rotarod), locomotor activity (open-field), and stereotypic behaviors. KYNA induced significant ataxia and stereotypic behaviors at 15 min, resolving by 45 min. In contrast, all analogs avoided acute motor deficits, with SZR-73 maintaining baseline rotarod performance and eliciting a delayed decrease in ambulation and inquisitiveness in open-field assays. These findings demonstrate that the structural optimization of KYNA successfully mitigates motor toxicity while retaining neuromodulatory activity. Here, we show that SZR-73 emerges as a lead candidate, combining transient therapeutic effects with preserved motor coordination. This study advances the development of safer neuroactive compounds, bridging a critical gap between preclinical innovation and clinical translation. Future work must validate chronic efficacy, disease relevance, and mechanistic targets to harness the full potential of KYNA analogs in treating complex neuropsychiatric disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kynurenic AcidSchizophreniaParkinson DiseaseBehavior, AnimalNeuroprotective AgentsAnimalsMiceMaleMice, Inbred C57BLMotor ActivityLocomotionDisease Models, Animal

Stichwörter der Autor:innen

Parkinson’s diseaseanimal modelsdrug designglutamatergic systemkynurenic acidmotor activityneuroprotective agentsschizophreniastructure–activity relationship

Substanzen

Kynurenic AcidNeuroprotective Agents

Autor:innen und Institutionen

  • HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged Danube Neuroscience Research Laboratory, Tisza Lajos krt. 113, H-6725 Szeged, Hungary.
  • Institute of Pharmaceutical Chemistry and HUN-REN-SZTE Stereochemistry Research Group, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.
  • Department of Neurology, Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary.

ORCID-Profile: Diána Martos, Bálint Lőrinczi, István Szatmári, Masaru Tanaka

Förderung

  • the National Research, Development, and Innovation Office-NKFIH K138125, SZTE SZA-OK-KKA
  • HUN-REN Hungarian Research Network
  • National Research, Development, and Innovation Office
  • Ministry of Human Capacities, Hungary
  • New National Excellence Program of the Ministry for Culture and Innovation

Zitieren

APA

Martos, D., Lőrinczi, B., Szatmári, I., Vécsei, L., & Tanaka, M. (2025). Decoupling Behavioral Domains via Kynurenic Acid Analog Optimization: Implications for Schizophrenia and Parkinson’s Disease Therapeutics. Cells. https://doi.org/10.3390/cells14130973

Vancouver

Martos D, Lőrinczi B, Szatmári I, Vécsei L, Tanaka M. Decoupling Behavioral Domains via Kynurenic Acid Analog Optimization: Implications for Schizophrenia and Parkinson’s Disease Therapeutics. Cells. 2025. doi:10.3390/cells14130973

BibTeX
@article{Martos2025,
  author = {Martos, Diána and Lőrinczi, Bálint and Szatmári, István and Vécsei, László and Tanaka, Masaru},
  title = {Decoupling Behavioral Domains via Kynurenic Acid Analog Optimization: Implications for Schizophrenia and Parkinson’s Disease Therapeutics},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14130973}
}
Kostenlos starten →